An alternative multimodal treatment is effective and safe for migrain

Леонид Чурилов; Jozélio de Carvalho; Aaron  Lerner; Natalia  Marques

doi:10.21638/spbu11.2021.405

Авторы

Леонид Чурилов St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation
Jozélio de Carvalho Institute for Health Sciences, Federal University of Bahia, Rua Augusto Viana, Palácio da Reitoria, Canela, Salvador, 40110-909, Brazil
Aaron Lerner Chaim Sheba Medical Center, 2, Derech Sheba, Ramat Gan, Israel
Natalia Marques VP Nutrição Funcional, 287, Rua Carlos Petit, Vila Mariana, São Paulo-SP, Brazil

DOI:

https://doi.org/10.21638/spbu11.2021.405

Аннотация

The objective of the article was to evaluate an alternative approach for migraine. The patients received an alternative multimodal approach (AMA) involving nutraceuticals, melatonin, and dietary changes. Six patients were included in the study. Comorbidities were observed in all patients and included hypertension, depression, anxiety, diabetes, asthma, silicone breast implants, and allergic rhinitis. Sleep disorders were observed in 67 % of the patients. Interestingly, after applying AMA, there was a remarkable improvement in all participants. Vitamin D levels surged significantly, and sleep improved in all patients with sleep disturbances. The number of days with migraine was reduced significantly. An improvement of VAS well-being was observed after AMA, and a reduction of the VAS migraine pain was noted. All migraineurs, except one, suspended the conventional preventive drugs for migraine. An AMA is effective and safe, without any side effects for migraine prevention and therapy.

Ключевые слова:

мигрень, головная боль, нутрицевтики, боль, витамин D, мелатонин, мигреники, благополучие

Скачивания

Данные скачивания пока недоступны.

Библиографические ссылки

References

Dodick D. W. Migraine. Lancet, 2018, vol. 391, no. 10127, pp. 1315–1330.

Ahn A. H, Basbaum A. I. Where do triptans act in the treatment of migraine? Pain, 2005, vol. 115, no. 1–2, pp. 1–4. https://doi.org/10.1016/j.pain.2005.03.008

Srikiatkhachorn A., Tarasub N., Govitrapong P. Effect of chronic analgesic exposure on the central serotonin system: a possible mechanism of analgesic abuse headache.Headache, 2000, vol. 40, no. 5, pp. 343–350.

D’Onofrio F., Raimo S., Spitaleri D., Casucci G., Bussone G. Usefulness of nutraceuticals in migraine prophylaxis. Neurol. Sci., 2017, May, vol. 38 (Suppl 1), pp. 117–120. https://doi.org/10.1007/s10072-017-2901-1

Graham J. R., Wolff H. G. Mechanism of migraine headache and action of ergotamine tartrate. Arch. Neurol. Psychiatry, 1938, vol. 39, pp. 737–763.

Anderson G. Integrating Pathophysiology in Migraine: Role of the Gut Microbiome and Melatonin. Curr. Pharm. Des., 2019, vol. 25, no. 3, pp. 3550–3562. https://doi.org/10.2174/1381612825666190920114611

Boutrid N., Rahmoune H. “3M”: Migraine, Microbiota and Melatonin. Med Hypotheses, 2019, Jun, vol. 127, p. 90. https://doi.org/10.1016/j.mehy.2019.04.001

Griauzdaitė K., Maselis K., Žvirblienė A., Vaitkus A., Jančiauskas D., Banaitytė-Baleišienė I., Kupčinskas L., Rastenytė D. Associations between migraine, celiac disease, non-celiac gluten sensitivity and activity of diamine oxidase. Med. Hypotheses, 2020, Sep., vol. 142, 109738. https://doi.org/10.1016/j.mehy.2020.109738

Rubino E., Rainero I., Garino F., Vicentini C., Govone F., Vacca A., Gai A., Gentile S., Govone G., Ragazzoni F., Pinessi L., Giordana M. T., Limone P. Subclinical hypothyroidism is associated with migraine: A case-control study. Cephalalgia, 2019, Jan., vol. 39, no. 1, pp. 15–20. https://doi.org/10.1177/0333102418769917

Cavestro C., Ferrero M. Migraine in Systemic Autoimmune Diseases. Endocr. Metab. Immune Disord. Drug. Targets, 2018, Feb. 13, vol. 18, no. 2, pp. 124–134. https://doi.org/10.2174/1871530317666171124124340

Rainero I., Govone F., Gai A., Vacca A., Rubino E. Is Migraine Primarily a Metaboloendocrine Disorder?Curr. Pain Headache Rep., 2018, vol. 22, no. 5, p. 36. https://doi.org/10.1007/s11916-018-0691-7

Churilov L. P., Stroev Y. I., Serdyuk I. Y., Kaminova-Mudzhikova O. M., Belyaeva I. V., Gvozdetsky A. N., Nitsa N. A., Mikhailova L. R. Autoimmune thyroiditis: Centennial jubilee of a social

disease and its comorbidity. Pathophysiology, 2014, Jun., vol. 21, no. 2, pp. 135–145. https://doi.org/10.1016/j.pathophys.2013.11.002

Long R., Zhu Y., Zhou S. Therapeutic role of melatonin in migraine prophylaxis: A systematic review.Medicine (Baltimore), 2019, vol. 98, no. 3, e14099. https://doi.org/10.1097/MD.0000000000014099

Orr S. L., Venkateswaran S. Nutraceuticals in the prophylaxis of pediatric migraine: Evidencebased review and recommendations. Cephalalgia, 2014, vol. 34, no. 8, pp. 568–583. https://doi.org/10.1177/0333102413519512

International Headache Society. The international classification of headache disorders, 3rd edn.Cephalalgia, 2018, vol. 38, pp. 1–211.

Togha M., Razeghi Jahromi S., Ghorbani Z., Martami F., Seifishahpar M. Serum Vitamin D Status in a Group of Migraine Patients Compared With Healthy Controls: A Case-Control Study. Headache, 2018, vol. 58, no. 10, pp. 1530–1540. https://doi.org/10.1111/head.13423

Song T. J., Chu M. K., Sohn J. H., Ahn H. Y., Lee S. H., Cho S. J. Effect of Vitamin D Deficiency on the Frequency of Headaches in Migraine. J. Clin. Neurol., 2018, vol. 14, no. 3, pp. 366–373.

Gazerani P., Fuglsang R., Pedersen J. G., Sørensen J., Kjeldsen J. L., Yassin H., Nedergaard B. S. A randomized, double-blinded, placebo-controlled, parallel trial of vitamin D3 supplementation in adult patients with migraine. Curr. Med. Res. Opin., 2019, vol. 35, no. 4, pp. 715–723.

Gonçalves A. L., Martini Ferreira A., Ribeiro R. T., Zukerman E., Cipolla-Neto J., Peres M. F. Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. J. Neurol. Neurosurg. Psychiatry, 2016, vol. 87, no. 10, pp. 1127–1132.

Lippi G., Mattiuzzi C., Meschi T., Cervellin G., Borghi L. Homocysteine and migraine. A narrative review. Clin. Chim. Acta, 2014, vol. 433, pp. 5–11.

Dolati S., Rikhtegar R., Mehdizadeh A., Yousefi M. The Role of Magnesium in Pathophysiology and Migraine Treatment. Biol. Trace Elem. Res., 2020, vol. 196, no. 2, pp. 375–383.

Chiu H. Y., Yeh T. H., Huang Y. C., Chen P. Y. Effects of Intravenous and Oral Magnesium on Reducing Migraine: A Meta-analysis of Randomized Controlled Trials. Pain Physician, 2016, vol. 19, no. 1, E97-E112.

Guilbot A., Bangratz M., Ait Abdellah S., Lucas C. A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: a prospective observational study. BMC Complement Altern. Med., 2017, vol. 17, no. 1, p. 433. https://doi.org/10.1186/s12906-017-1933-7

Nagata E., Shibata M., Hamada J., Shimizu T., Katoh Yu., Gotoh K., Suzuki N. Plasma 5-hydroxytryptamine (5-HT) in migraine during an attack-free period. Headache, 2006, vol. 46, no. 4, pp. 592–596.

Titus F., Dávalos A., Alom J., Codina A. 5-Hydroxytryptophan versus methysergide in the prophylaxis of migraine. Randomized clinical trial.Eur. Neurol., 1986, vol. 25, no. 5, pp. 327–329.

Chiu T. F., Chen L. L., Su D. H., Lo H.-Y., Chen C.-H., Wang S.-H., Chen W.-L. Rhodiola crenulate extract for prevention of acute mountain sickness: a randomized, double-blind, placebo-controlled, crossover trial. BMC Complement Altern. Med., 2013, vol. 13, p. 298.

Olsson E. M., von Schéele B., Panossian A. G. A randomised, double-blind, placebo-controlled, parallel-group study of the standardized extract shr-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue. Planta Med., 2009, vol. 75, no. 2, pp. 105–112.

Zhao Zhongzhen (Ed.). An Illustrated Chinese Materia Medica. Hong Kong, Singapore: World Scientific Publishers, 2004. 544 p. https://doi.org/10.1142/5634

Gross E. C., Lisicki M., Fischer D., Sándor P. S., Schoenen J. The metabolic face of migraine — from pathophysiology to treatment. Nat. Rev. Neurol., 2019, vol. 15, no. 11, pp. 627–643. https://doi.org/10.1038/s41582-019-0255-4

Mehrabani S., Askari G., Miraghajani M., Tavakoly R., Arab A. Effect of coenzyme Q10 supplementation on fatigue: A systematic review of interventional studies. Complement Ther. Med., 2019, vol. 43,pp. 181–187.

Luo C., Xu X., Wei X., Feng W., Huang H., Liu H., Xu R., Lin J., Han L., Zhang D. Natural medicines for the treatment of fatigue: Bioactive components, pharmacology, and mechanisms. Pharmacol. Res.,2019, vol. 148. https://doi.org/10.1016/j.phrs.2019.104409.

Goschorska M., Gutowska I., Baranowska-Bosiacka I., Barczak K., Chlubek D. The Use of Antioxidants in the Treatment of Migraine. Antioxidants (Basel), 2020, vol. 9, no. 2, p. 116. https://doi.org/10.3390/antiox9020116

Uguz F., Sahingoz M., Gungor B., Aksoy F., Askin R. Weight gain and associated factors in patients using newer antidepressant drugs. Gen. Hosp. Psychiatry, 2015, vol. 37, no. 1, pp. 46–48.

Domecq J. P., Prutsky G., Leppin A., Sonbol M. B., Altayar O., Undavalli C., Wang Z., Elraiyah T., Brito J. P., Mauck K. F., Lababidi M. H., Prokop L. J., Asi N., Wei J., Fidahussein S., Montori V. M., Murad M. H. Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab., 2015, vol. 100, no. 2, pp. 363–370.

Geiker N. R. W., Astrup A., Hjorth M. F., Sjödin A., Pijls L., Markus C. R. Does stress influence sleep patterns, food intake, weight gain, abdominal obesity and weight loss interventions and vice versa?Obes. Rev., 2018, vol. 19, no. 1, pp. 81–97.

Sanghez V., Razzoli M., Carobbio S., Campbell M., McCallum J., Cero C., Ceresini G., Cabassi A., Govoni P., Franceschini P., de Santis V., Gurney A., Ninkovic I., Parmigiani S., Palanza P., Vidal-Puig A., Bartolomucci A. Psychosocial stress induces hyperphagia and exacerbates diet-induced insulin resistance and the manifestations of the Metabolic Syndrome. Psychoneuroendocrinology, 2013, vol. 38, no. 12, pp. 2933–42. https://doi.org/10.1016/j.psyneuen.2013.07.022

González-Hernández A., Marichal-Cancino B. A., Maassen Van Den Brink A., Villalón C. M. Side effects associated with current and prospective antimigraine pharmacotherapies. Expert Opin. Drug Metab. Toxicol.,2018, vol. 14, no. 1, pp. 25–41.

Vila-Pueyo M. Targeted 5-HT1F Therapies for Migraine. Neurotherapeutics, 2018, vol. 15, no. 2, pp. 291–303. https://doi.org/10.1007/s13311-018

Tauchen J. Natural Products and their (Semi-)Synthetic Forms in the Treatment of Migraine: History and Current Status. Curr. Med. Chem., 2020, vol. 27, no. 23, pp. 3784–3808. https://doi.org/10.2174/0929867326666190125155947